基本信息来源于合作网站,原文需代理用户跳转至来源网站获取       
摘要:
The efficacy of oral treatment with chewable tablets containing afoxolaner 2.27% w/w (NexGard?, Merial, now part of Boehringer-Ingelheim) or 1.875% w/w of afoxolaner and 0.375% w/w milbemycin oxime (NexGard Spectra?, Merial, now part of Boehringer-Ingelheim) was each assessed in eight dogs diagnosed with generalized demodicosis in this parallel group designed, blinded, randomized, single center negative controlled, efficacy study. Afoxolaner at the therapeutic dose (as close as possible to 2.5 mg/kg) was administered to Group 2 dogs, and afoxolaner (as close as possible to 2.5 mg/kg) with milbemycin oxime at 0.5 mg/kg was administered to Group 3 dogs on Days 0, 28 and 56. All dogs were observed once daily for general health starting on Day -7 until Day 84. All dogs were clinically examined on Days -7, -2, 14, 28, 42, 56, 70 and 84. Dogs were weighed on Days -7, -2, 27, 55, and 84. Live mite counts (based on five scrapings per dog and occasion) and clinical assessments, including photographic documentation, were performed on Days -2, 28, 56 and 84. Three monthly treatments with NexGard or NexGard Spectra against generalized demodicosis in dogs were highly effective resulting in a 99.9% and 100% efficacy against mites, respectively. After treatment with NexGard, only three live mites were recovered in five scrapings in one dog on Day 84. After treatment with NexGard Spectra, no mites were recovered in any scraping on any dogs in this group by Day 84. Both treatments resulted in a marked reduction of skin lesions and >90% hair-regrowth at three months after the initial treatment. Reduction of live mite counts was consistent with reduction in the extent and severity of the skin changes. Although the arithmetic mean mite numbers in the negative control group decreased slightly during the study, infection persisted in 7 of the 8 control dogs until Day 84. Both treatment groups of dogs showed a marked improvement of the associated dermatologic signs with steady improvement over the three-month treatment period.
推荐文章
A combined IR and XRD study of natural well crystalline goethites(α-FeOOH)
Crystallinity
Goethite
IR-spectrometry
X-ray diffraction
XRD rietveld refinement
Characterization
Milbemycin Oxime半抗原设计及其抗体制备
milbemycin oxime
半抗原
酶联免疫吸附法(ELISA)
话语标记语well的语用功能
话语标记语
well
语用功能
动态性
内容分析
关键词云
关键词热度
相关文献总数  
(/次)
(/年)
文献信息
篇名 Efficacy of Once-Monthly Doses of Oral Afoxolaner and Afoxolaner/Milbemycin Oxime in a Well-Controlled Study for the Treatment of Canine Generalized Demodicosis
来源期刊 兽医学(英文) 学科 医学
关键词 DEMODEX CANIS Demodicosis TREATMENT Afoxolaner NexGard NexGard Spectra Dog
年,卷(期) syxyw_2018,(12) 所属期刊栏目
研究方向 页码范围 250-265
页数 16页 分类号 R73
字数 语种
DOI
五维指标
传播情况
(/次)
(/年)
引文网络
引文网络
二级参考文献  (0)
共引文献  (0)
参考文献  (0)
节点文献
引证文献  (0)
同被引文献  (0)
二级引证文献  (0)
2018(0)
  • 参考文献(0)
  • 二级参考文献(0)
  • 引证文献(0)
  • 二级引证文献(0)
研究主题发展历程
节点文献
DEMODEX
CANIS
Demodicosis
TREATMENT
Afoxolaner
NexGard
NexGard
Spectra
Dog
研究起点
研究来源
研究分支
研究去脉
引文网络交叉学科
相关学者/机构
期刊影响力
兽医学(英文)
月刊
2165-3356
武汉市江夏区汤逊湖北路38号光谷总部空间
出版文献量(篇)
118
总下载数(次)
0
论文1v1指导